Fig. 1From: Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional studyKaplan–Meier method for PSA-progression-free survival estimation, PSA, prostate-specific antigen; CI, confidence interval.Back to article page